Pharming Group N.V. announces the reimbursement of RUCONEST® in Spain

Pharming Group announces that an agreement has been reached with the Spanish Ministry of Health to grant reimbursement for RUCONEST® (conestat alfa) in Spain. We are delighted with this positive reimbursement decision by the Spanish Ministry of Health, as it means patients in Spain in need of new treatment options for hereditary angioedema will now be able to access RUCONEST® — Sijmen de Vries - CEO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗